HK Stock Market Move | OCUMENSION-B(01477) rose over 16% in the afternoon. The first patient was enrolled in the Phase III clinical trial of OT-211 for the treatment of dry eye syndrome.

OCUMENSION-B (01477) rose over 16% in the afternoon, and as of press time, it had risen by 15.33%, closing at 8.5 Hong Kong dollars, with a turnover of 26.0687 million Hong Kong dollars. In terms of news, Ocumension Bio announced that the Phase III clinical trial of OT-211 (AR-15512) in China has completed the enrollment of the first patient. OT-211 (AR-15512) is a 0.003% concentration eye drop formula, and it is the first TRPM8 agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of dry eye disease (DED). The successful enrollment of the first patient marks an important milestone in the clinical development of OT-211 in China and demonstrates the group's commitment to advancing innovative therapies for DED patients. Public information shows that Alcon Inc. developed the 0.003% concentration eye drop formula of AR-15512 and completed a Phase IIb and three Phase III clinical trials. OT-211 (AR-15512) was approved by the FDA on May 28, 2025 for the treatment of signs and symptoms of DED. After entering into a strategic partnership with Alcon Group in October 2024, the group has obtained exclusive licenses from Alcon Group for the development, manufacturing, contract manufacturing, import, export, and sales of OT-211 (AR-15512) in mainland China.